uniQure has secured a Type A meeting with the U.S. Food and Drug Administration to discuss the Biologics License Application data package supporting accelerated approval of AMT-130, its investigational gene therapy for Huntington’s disease. The meeting, set for the first quarter of 2026, will focus on safety and efficacy data from the ongoing Phase I/II trial, which enrolled 26 patients and demonstrated a 75% slowing of composite Unified Huntington’s Disease Rating Scale progression at 36 months. CEO Matt Kapusta emphasized uniQure’s commitment to expediting access for patients given the profound unmet need, noting that the company will provide a regulatory update after receipt of official meeting minutes.

Following initial discussions with FDA reviewers, uniQure encountered a reversal on the use of external natural history controls for AMT-130’s BLA, forcing a delay in submission plans. The FDA’s request for additional randomized data or a confirmatory cohort raises the prospect of a Phase III study, prolonging the regulatory timeline by up to 18 months. While the Phase I/II results remain compelling—showing durable transgene expression and no treatment-related serious adverse events—the company now faces the prospect of generating fresh clinical evidence to satisfy the agency’s standards for a single-arm accelerated approval.

With $694 million in cash and marketable securities at the end of the third quarter of 2025, uniQure is positioned to fund its ongoing Huntington’s program and advance other pipeline assets, including candidates for refractory temporal lobe epilepsy and Fabry disease. Operating expenses for the gene therapy research and development segment rose by 42% year-over-year to $118 million in the first nine months of 2025, reflecting increased manufacturing scale-up and trial enrollment. Management forecasts cash runway into late 2027, assuming the initiation of a potential confirmatory study for AMT-130 and continued investment in platform technologies.

Investors will closely monitor the official FDA meeting minutes for clarity on AMT-130’s path to approval, particularly regarding trial design adjustments and potential accelerated pathways such as Breakthrough Therapy or RMAT designations. The company’s ability to leverage its hemophilia B success as proof of manufacturing consistency may bolster discussions, but any requirement for a Phase III trial could materially diminish near-term value. Analysts project that uniQure’s share of the Huntington’s gene therapy market could exceed $2 billion annually upon approval, underscoring the importance of a favorable regulatory outcome in driving long-term investor returns.